3 August 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Proteome Sciences completes milestone towards launch of Single Cell Proteomics services
Proteome Sciences is pleased to announce that the Company has completed the next milestone towards the launch of Single Cell Proteomics services, which will be known as SysQuant® SCP, with the installation of a cellenONE® (Cellenion, France) platform that allows the semi-automated preparation of up to 2,700 cells per week. The Company anticipates that most commercial projects will require analysis of 500 - 1,000 cells using TMTpro™ multiplexing, and it will be able to perform 1-2 such studies per week. Working with such small samples is challenging and will be beyond the means of many academic and industrial research groups. The Company believes its employees' experience as inventors and manufacturers of TMT® and TMTpro™ reagents gives the Company unique insights into their use in this complex setting.
Following initial experiments, the Company expects coverage of between 1,000 and 1,500 proteins per cell. The Company expects to complete the platform and process validation in Q3 2022 and then launch the dedicated multiplex SysQuant® SCP services before the end of the year. This complements the expansion of the Company's mass spectrometer platforms late last year and will establish Proteome Sciences as the premier provider of single cell proteomics.
Commenting on the development of SysQuant® SCP, Dr. Ian Pike, Chief Scientific Officer said:
"It is clear that the demand for a standardized service is growing rapidly. The use of TMTpro™ reagents is greatly enhancing coverage in studies of 100s of individual cells and provides the throughput necessary for large studies needed in pharmaceutical research. By isolating and labelling each cell with TMTpro™ tags and then mixing to make a more concentrated sample on the cellenONE® platform, we can explore the true diversity of functional biology in every disease, with the potential to identify new drug targets and diagnostic biomarkers. The system provides the level of throughput required for our initial plans to launch a SysQuant® SCP service and is scalable to rapidly increase capacity as the market opportunity grows. This is a major step in the process and we have further exciting developments for single cell proteomics planned for the future".
For further information:
| Proteome Sciences plc Dr Mariola Soehngen, Chief Executive Officer & | |
| Dr Ian Pike, Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
|
Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
| John Depasquale / Jeremy Porter | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.